Different turnover rate of hepatitis c clearance by different treatment regimen using interferon-beta

Journal of Hepatology

Volumn 33, Issue 2, 2000, Pages 313-322

  Shiratori, Yasushi ^a,i   Perelson, Alan S ^b   Weinberger, Leor ^b   Imazeki, Fumio ^c   Yokosuka, Osamu ^c   Nakata, Ryo ^d   Ihori, Masashi ^d   Hirota, Katsutaro ^e   Ono, Naomi ^f   Kuroda, Hisamoto ^g   Motojima, Teiji ^g   Nishigaki, Masaru ^h   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^e Mito Saiseikai General Hospital   (Japan)

^f SASAKI INSTITUTE   (Japan)

^g Motojima General Hospital   (Japan)

^h UNIVERSITY OF SHIZUOKA   (Japan)

ⁱ Dept Int Med (Gastroenterol) U   (Japan)

Author keywords

Amplicor HCV monitor assay; HCV RNA level; Interferon beta; Twice a day administration; Viral dynamics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOALBUMINEMIA; LIVER BIOPSY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0033914781     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80373-6     Document Type: Article

References (37)

1. Poynard T, Bedossa P, Oplon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 349:1997;825-832.
2. Tong MJ, Neveen S, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 332:1995;1463-1466.
3. Hoofnagle JH, Mullen KD, Jones DB, Rustigi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med. 315:1986;1575-1578.
4. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pre-treatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 22:1995;1050-1056.
5. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology. 22:1995;1326-1329.
6. Lau JYN, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-alfa in chronic hepatitis C. Lancet. 342:1993;1208-1209.
7. Hoofnagle JH, De Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 336:1997;347-356.
8. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology. 113:1997;558-566.
9. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 26:(Suppl 1):1997;71S-77S.
10. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 26:(Suppl 1):1997;122S-127S.
11. Poynard T, Marcellin P, Lee SS, Niderau C, Minuk G, Ideo G, et al. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
12. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustigi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 339:1998;1485-1492.
13. Ampurdanes S, Olmedo E, Maluenda MD, Forms X, Lopez-Labrador FX, Costa J, et al. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol. 25:1996;827-832.
14. Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, et al. Loss of serum HCV RNA at week 4 of interferon-alfa therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol. 46:1995;109-115.
15. Lee WM, Reddy R, Tong MJ, Black M, van Leeuwen DJ, Hollinger FB, et al. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology. 28:1998;1411-1415.
16. Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology. 27:1998;1149-1156.
17. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science. 271:1996;1582-1586.
18. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deuesch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
19. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
20. Zeuzem S, Schnidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology. 23:1996;366-371.
21. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology. 26:1997;226-231.
22. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alfa therapy. Science. 282:1998;103-107.
23. Yasui K, Okanoue T, Murakami Y, Itoh Y, Minami M, Sakamoto S, et al. Dynamics of hepatitis C viremia following interferonalfa administration. J Infect Dis. 177:1998;1475-1479.
24. Chambers HF, Sande MA. Antimicrobial agents: general consideration. Hardman JG, Limbird LE, Molinoff PB, Ruddon R, Goodman Gulman A. Goodman Gilman's The Pharmacological Basis of Therapeutics, 9th ed. 1996;1029-1056 McGraw-Hill, New York.
25. Hayden FG. Antiviral agents. Hardman JG, Limbird LE, Molinoff PB, Ruddon R, Goodman Gulman A. Goodman Gilman's The Pharmacological Basis of Therapeutics, 9th ed. 1996;1191-1223 McGraw-Hill, New York.
26. Samuel CE. Antiviral action of interferon - interferon-regulated cellular protein and their surprising selective antiviral activities. Virology. 183:1991;1-11.
27. Sen GC, Ransohoff RM. Interferon-induced antiviral actions and their regulation. Adv Virus Res; 42: 57-102.
28. Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, et al. Rinavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol. 46:1998;563-570.
29. Takano S, Satomura Y, Omata M. Effect of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Gastroenterology. 107:1994;805-811.
30. Furusyo N, Hayashi J, Ohmiya M, Sawayama Y, Atiyama I, Kinukawa N, et al. Differences between interferon-alfa and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci. 44:1999;608-617.
31. Okamoto H, Kurai K, Okada SI, Yamamoto K, Iizuka H, Tanaka T, et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolated: comparative study of four distinct genotypes. Virology. 188:1992;331-341.
32. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1994;1513-1520.
33. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1993;1501-1504.
34. Young KK, Archer JJ, Yokosuka O, Omata M, Resnick RM. Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: comparison with nested amplification and antibody testing. J Clin Microbiol. 33:1995;654-657.
35. Shiratori Y, Kato N, Tamatsukuri S, Yoshida H, Kawabe T, Nakata R, et al. Real-time monitoring of HCV RNA by single-tube assay kit and potential importance for predicting virological sustained response in patients with chronic hepatitis C. J Gastroenterol Hepatol. 11:1996;705-711.
36. Shiratori Y, Kato N, Yokosuka O, Hashimoto E, Hayashi N, Nakamura A, et al. Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon. J Hepatol. 27:1997;437-444.
37. Shiratori Y, Yokosuka O, Nakata R, Ihori M, Hirota K, Katamoto T, et al. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology. 29:1999;1573-1580.